St. Louis, MO (PRWEB) April 07, 2011
Reliable Biopharmaceutical Corporation (“RBC”) announced that their patent for Fondaparinux Sodium was published by the International Bureau of WIPO, Patent International Publication Number: WO 2011/014793 A2.
The present invention relates to processes for the synthesis of the Factor Xa anticoagulant Fondaparinux, and related compounds.
The invention also relates to protected pentasaccharide intermediates and to an efficient and scalable process for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
“This work represents the diversity of technical scientific creativity that is held at Reliable“, said David Feldker, President and CEO of Reliable Biopharmaceutical Corp. “By finding ways to bring Generic Pharmaceuticals to market sooner, RBC is working to make Health Care more affordable.”
About Reliable Biopharmaceutical Corporation
Founded in 1968, RBC is an integrated developer and manufacturer of active pharmaceutical ingredients ("APIs") and High Purity Ingredients ("HPIs") for pharmaceuticals and biologics. RBC has established a strong position as a leading developer and manufacturer of complex generic injectable APIs. The Company has developed 18 generic injectable APIs to date that have been approved as Type II Drug Master Files by the FDA and has 14 more in various stages of development. RBC's products are the active ingredients for leading generic injectable drugs that treat cancer, heart disease, hypertension, anxiety and other serious and life threatening illnesses. RBC also manufactures critical processing aids for the pharmaceutical industry and currently supplies these products to many of the world's leading pharmaceutical and biotechnology companies. RBC is a portfolio company of Med Opportunity Partners, LLC.
About Med Opportunity Partners, LLC
Med Opportunity Partners, LLC (http://www.MedOpportunity.com) is a Greenwich, CT- based operating oriented private equity firm that acquires leading healthcare companies at their growth stage. MEDOP is dedicated to investing in companies that drive healthcare innovation, growth and consolidation. Founded by seasoned healthcare operators and investors, MEDOP partners with companies that can benefit from its extensive industry knowledge, relationships and proven operating and transaction experience. MEDOP receives funding from prominent investors including pension funds, endowments, insurance companies, and private families.